EX-10.11





 Exhibit 10.11 

AMENDMENT AGREEMENT 
 TO

 SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT 

THIS AMENDMENT AGREEMENT TO SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT (the
“Agreement”) is made and entered into as of November 19, 2019 by and among: 
  

	 	1.	 Genetron Holdings Limited
(泛生子基因(控股)有限公司), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the “Company”);



  

	 	2.	 Genetron Health (Hong Kong) Company Limited
(泛生子基因(香港)有限公司), a company organized and existing under the laws of Hong Kong (the “HK Co.”); 



 

	 	3.	 Genetron (Tianjin) Co., Ltd. (天津泛生子有限公司), a
wholly foreign owned enterprise organized and existing under the laws of the PRC (the “WFOE”); 


  

	 	4.	 Genetron Health (Beijing) Co., Ltd.
(北京泛生子基因科技有限公司), a limited liability company organized and existing under the laws of PRC (the “PRC Affiliate”); 



 

	 	5.	 Each of the persons as set forth in Table A of Schedule I attached hereto (the
“Founders” and each, a “Founder”); 


  

	 	6.	 The entity as set forth in Table B of Schedule I attached hereto (the “BVI Company”);
and 


  

	 	7.	 VIVO CAPITAL FUND IX, L.P., a limited partnership organized and existing under the laws of the United States
(the “Investor” or “VIVO”). 


 Each of the foregoing Parties is referred to herein
individually as a “Party” and collectively as the “Parties”. The capitalized terms used and not defined herein shall have the same meaning as ascribed to them in the Purchase Agreement (as defined below). 

RECITALS 
 The Parties
have entered into SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT on October 1, 2019 (the “Purchase Agreement”). The Parties desire to enter
into this Agreement to amend certain provisions of the Purchase Agreement. 

  
 1 













 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
  

	1.	 Section 3.02 (b) of the Purchase Agreement shall be amended by deleting in its entirety and
replacing it with the following: 


 (b) Preferred Shares. Immediately prior to the Closing, (i) a total of
47,600,000 authorized Series A-1 Preferred Shares, 44,404,500 of which are issued and outstanding; (ii) a total of 19,760,000 authorized Series A-2 Preferred
Shares, 17,544,000 of which are issued and outstanding; (iii) a total of 43,363,500 authorized Series B Preferred Shares, 41,842,000 of which are issued and outstanding; (iv) a total of 60,359,500 authorized Series C Preferred Shares, all
of which are issued and outstanding; (v) a total of 15,205,000 authorized Series C-2 Preferred Shares, of which none was issued and outstanding; (vi) a certain number of Series D Preferred Shares,
which are the same with the number of Series D Preferred Shares immediately prior to the Series D Closing as stipulated in Series D Purchase Agreement and of which none was issued and outstanding. 

 

	2.	 Section 6.06 of the Purchase Agreement shall be amended by deleting in its entirety and replacing
it with the following: 


 Upon or immediately prior to the Closing, the Board of Directors and the shareholders of the
Company shall have duly reserved 20,830,100 Ordinary Shares to be issued to the employees, officers, directors, or consultants of a Group Company in accordance with the 2019 New Share Incentive Plan. 

 

	3.	 The definition of “Preferred Shares” in Annex A (Definitions) of the Purchase Agreement shall be
amended by deleting in its entirety and replacing it with the following: 


 “Preferred Shares” shall mean the
Company’s Series D Preferred Shares, the Series C-2 Preferred Shares, the Series C Preferred Shares, the Series B Preferred Shares, the Series A Preferred Shares and/or other preferred shares of the
company that may be issued from time to time. 
  

	4.	 The definition of “Series C-1 Preferred Share(s)” in Annex A
(Definitions) of the Purchase Agreement shall be amended by deleting in its entirety and replacing it with the following: 



“Series C Preferred Share(s)” shall mean the Company’s series C convertible preferred shares, par value US$0.00002 per
share. 
  

	5.	 The definition of “2019 New Share Incentive Plan” in Annex A (Definitions) of the Purchase Agreement
shall be amended by deleting in its entirety and replacing it with the following: 


 “2019 New Share
Incentive Plan” shall mean the management incentive plan to be adopted by the Company after the Closing, covering the grant of up to 20,830,100 Ordinary Shares (or options therefor) (as adjusted for share splits, share dividends,
combinations, recapitalizations and similar events) to the employees, officers, directors, or consultants of a Group Company. 

  
 2 














	6.	 The term “Series C-1” in Schedule III (Capitalization
Structure Immediately After the Closing) of the Purchase Agreement shall be amended, in each instance, by deleting in its entirety and replacing it with “Series C”. 



 

	7.	 The Parties confirm that the Purchase Agreement as amended hereby shall continue to remain in full force and
effect and that the Purchase Agreement and this Agreement shall be read and construed as one agreement and be operative and binding on the Parties. For avoidance of doubt, the Purchase Agreement shall, where the context so requires, be read and
construed throughout so as to incorporate the amendments hereinbefore made. 


  

	8.	 This Agreement shall be effective upon execution by each of the Parties hereto. 



 

	9.	 This Agreement shall be governed by and construed exclusively in accordance with the laws of the Hong Kong
without regard to principles of conflicts of law thereunder. 


  

	10.	 The Parties agree to negotiate in good faith to resolve any dispute between them regarding this Agreement. If
the negotiations do not resolve the dispute to the reasonable satisfaction of all Parties within thirty (30) days, such dispute shall be referred to and finally settled by arbitration at the Hong Kong International Arbitration Centre (the
“HKIAC”) for arbitration in Hong Kong. The arbitration shall be conducted in accordance with the HKIAC Administered Arbitration Rules in force at the time of the initiation of the arbitration. 



 

	11.	 This Agreement may be executed (including electronic signature) in any number of counterparts, each of which
shall be an original, but all of which together shall constitute one instrument. 


 ——REMAINDER OF THIS PAGE
LEFT INTENTIONALLY BLANK—— 

  
 3 













 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

			
	THE COMPANY:
	
	 Genetron Holdings Limited (泛生子基因(控股)

有限公司)

		
	By:	 	/s/ Wang Sizhen
	Name: Wang Sizhen
	Title: Director
	
	THE BVI COMPANY:
	
	FHP Holdings Limited
		
	By:	 	/s/ Wang Sizhen
	Name: Wang Sizhen
	Title: Director
	
	THE HK CO.:
	
	 Genetron Health (Hong Kong) Company Limited

(泛生子基因(香港)有限公司)

		
	By:	 	/s/ Wang Sizhen
	Name: Wang Sizhen
	Title: Director














 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

			
	THE WFOE:
	
	Genetron (Tianjin) Co., Ltd. (天津泛生子有限公司)(Seal)
		
	By:	 	/s/ Wang Sizhen
	Name: Wang Sizhen
	Title: Legal Representative
	
	THE PRC AFFILIATE:
	
	Genetron Health (Beijing) Co., Ltd. (北京泛生子基因科技有限公司) (Seal)
		
	By:	 	/s/ Wang Sizhen
	Name: Wang Sizhen
	Title: Legal Representative














 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

	
	 THE FOUNDERS:

	
	 /s/ Wang Sizhen

	 Name: Wang Sizhen















 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

	
	 THE FOUNDERS:

	
	 /s/ Yan Hai

	 Name: Yan Hai















 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

	
	 THE FOUNDERS:

	
	 /s/ He Weiwu

	 Name: He Weiwu















 IN WITNESS WHEREOF, the parties hereto have caused their respective duly authorized representatives to
execute this Agreement as of the date and year first above written. 
  

			
	THE INVESTOR:
	
	VIVO CAPITAL FUND IX, L.P.
	By: Vivo Capital IX, LLC
		
	By:	 	/s/ Frank Kung
	Name: Frank Kung
	Title: Managing Member